Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - Net
Ratios

Tandem Diabetes Care (TNDM) R&D In Process (2022 - 2025)

Tandem Diabetes Care's R&D In Process history spans 3 years, with the latest figure at $75.2 million for Q1 2025.

  • For Q1 2025, R&D In Process changed N/A year-over-year to $75.2 million; the TTM value through Dec 2025 reached $75.2 million, changed N/A, while the annual FY2025 figure was $75.2 million, N/A changed from the prior year.
  • R&D In Process reached $75.2 million in Q1 2025 per TNDM's latest filing, down from $78.8 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $78.8 million in Q1 2023 to a low of $23000.0 in Q4 2022.
  • Average R&D In Process over 3 years is $46.2 million, with a median of $53.1 million recorded in 2022.